← Leaderboards
Shailja Pathania
University Of Massachusetts Boston
$2,528,473
Attributed
$2,572,737
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $712.1K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,572,737 · 5
By mechanism
R01$1,756,405 · 1
R15$456,353 · 1
U54$207,479 · 2
R03$152,500 · 1
Top collaborators
- Jill A. Macoska1 shared
Others in their field
Other Emerging Leaders on “Replication Stress”
- Hans Joerg Moebius · Athira Pharma, Inc.$6,312,103
- Charles Bernick · Athira Pharma, Inc.$6,312,103
- Jennifer A. Lewis · Harvard University$4,481,731
- Jonathan Kil · Sound Pharmaceuticals, Inc.$4,174,965
- Alison G Lee · Icahn School Of Medicine At Mount Sinai$4,080,495
- James M Dewar · Vanderbilt University$3,568,897
Research focus
Replication StressCellsMutation CarrierTumorDesignTissuesChemoresistanceApplications GrantsIncidenceHigh RiskMammary Gland ParenchymaDna DamageInsightMutantMalignant Neoplasm Of ProstateNeoplastic CellMalignant Breast NeoplasmDna Sequence AlterationMalignant NeoplasmsBrca2 GeneEventGerm-Line MutationMolecularPrevention Strategy
Grant awards (10)
Mechanisms Underlying Replication Stress And Genome Instability Upon BRCA2 Deficiency$712,077
R01 · FY2025 · CA · contact PI
Mechanisms Underlying Replication Stress And Genome Instability Upon BRCA2 Deficiency$336,543
R01 · FY2024 · CA · contact PI
Mechanisms Underlying Replication Stress And Genome Instability Upon BRCA2 Deficiency$358,941
R01 · FY2023 · CA · contact PI
A Novel BRCA1 Heterozygosity Driven Breast Cancer Mouse Model to Identify Tumor Initiating Events and Therapeutic Strategies$76,250
R03 · FY2023 · CA · contact PI
Mechanisms Underlying Replication Stress And Genome Instability Upon BRCA2 Deficiency$348,844
R01 · FY2022 · CA · contact PI
A Novel BRCA1 Heterozygosity Driven Breast Cancer Mouse Model to Identify Tumor Initiating Events and Therapeutic Strategies$76,250
R03 · FY2022 · CA · contact PI
High Frequency of CHD1 Loss in BRCA2- Deficient African American Prostate Tumors Drives Tumor Formation by Suppressing Replication Stress$57,950
U54 · FY2022 · CA · contact PI
High Frequency of CHD1 Loss in BRCA2- Deficient African American Prostate Tumors Drives Tumor Formation by Suppressing Replication Stress$61,000
U54 · FY2021 · CA · contact PI
Base Excision Repair Deficiency as a Risk Modifier in BRCA2 Associated Cancer$456,353
R15 · FY2019 · CA · contact PI
Environmental Carcinogens Drive Risk for Breast Cancer in BRCA2 Mutation Carriers$88,529
U54 · FY2019 · CA · contact PI